Calgary-based Orpyx Medical Technologies Inc. is working with Onduo, a joint venture between Verily (a subsidiary of Alphabet) and Sanofi for technology that helps prevent foot ulcers.
“Managing diabetes is a 24/7 job, and we want to make access to care and monitoring easier for members.”
Orpyx’s foot sensor technology is installed in foot insoles and monitors foot pressure on diabetic patients and those with foot numbness. The tech will then send alerts to smartphones or smartwatches when a person is at risk for a foot injury, so preventative actions can be taken. The company indicated that 25 percent of people with diabetes develop foot ulcers over their lifetime, with one in five of those people experiencing complications that lead to amputation.
“Orpyx helps people with diabetes to prevent foot ulcers, by providing insight that protects foot health and mobility, and reduces the risk of complications that can lead to limb loss,” Breanne Everett, CEO of Orpyx, said in a statement. “We are pleased to extend access to our foot sensor technology to the Onduo member community, and invite Orpyx US patients to take advantage of Onduo’s services.”
Onduo will be integrating Orpyx’s wireless foot monitoring tech with its software, which matches diabetics with personalized lifestyle and clinical interventions. The program will be offered to select users this year.
“Managing diabetes is a 24/7 job, and we want to make access to care and monitoring easier for members,” Dr. Josh Riff, CEO of Onduo said in a statement. “We are thrilled to partner with the Orpyx to help keep members walking and living actively in our community.”
Orpyx was awarded a patent for its technology in the US just last year.
Image via Pixabay.